Table 1.

Baseline Characteristics

	All (N = 112)	DCA > 58 ng/mL (n = 56)	DCA ≤ 58 ng/mL (n = 56)	P
Age (years)	65.7 ± 12.2	68.4 ± 11.0	63 ± 12.8	0.04
Male sex	54 (48%)	25 (44%)	29 (52%)	0.6
Race				0.1
White	87 (78%)	47 (84%)	40 (71%)
Black	13 (12%)	3 (5%)	10 (18%)
Other	12 (10%)	6 (11%)	5 (11%)
Diabetes	63 (56%)	35 (63%)	28 (50%)	0.3
Hypertension	110 (98%)	54 (96%)	56 (100%)	0.5
Coronary Artery Disease	25 (22%)	16 (29%)	9 (16%)	0.2
Hyperlipidemia	100 (89%)	51 (91%)	49 (88%)	0.8
BMI	31.5 ± 7.3	32.4 ± 7.4	30.7 ± 7.0	0.2
eGFR	31.5 ± 8.7	31.7 ± 7.5	31.3 ± 9.6	0.5
Mineral Metabolites
Calcium (mg/dL)	9.3 ± 0.4	9.3 ± 0.4	9.3 ± 0.4	0.7
Phosphate (mg/dL)	4.2 ± 0.4	4.1 ± 0.4	4.3 ± 0.4	0.04
1,25(OH)2D (pg/mL)	26.3 ± 10.9	25.7 ± 10.4	27.0 ± 11.5	0.7
PTH (pg/mL)	79.6 ± 54.1	75.3 ± 54.7	83.8 ± 53.6	0.3
FGF-23 (pg/mL)	215.0 [132.0–307.9]	241.3 [149.6–320.6]	202.5 [128.4–280.5]	0.5
CAC volume score	246.0 [43.0–743.0]	474.0 [126.5–1017.5]	143.0 [0.0–525.0]	0.004
Log CAC volume score	2.1 ± 1.1	2.5 ± 0.9	1.7 ± 1.2	<0.001
BMD (g/cm2)	113.1 ± 40.4	99.6 ± 33.7	125.5 ± 42.4	0.007
DCA (ng/mL)	58.4 [29.2–111.8]	111.8 [80.3–168.2]	28.7 [16.5–41.7]	<0.001
Log DCA	1.7 ± 0.5	2.1 ± 0.3	1.4 ± 0.3	0.005
Treatment assignment				0.3
Active	72	39	33
Placebo	40	17	23

Note: Values for categorical variables are given as number (percentage); values for continuous variables, as mean ± standard deviation or median [interquartile range]. Conversion factors for units: calcium in mg/dL to mmol/L, ×0.2495; 1,25(OH)₂D in pg/mL to pmol/L, ×2.6;

Abbreviations: BMD, bone mineral density; BMI, body mass index; eGFR, estimated glomerular filtration rate; 1,25(OH)₂D, 1,25-dihydroxyvitamin D; PTH, parathyroid hormone; FGF-23, fibroblast growth factor 23; CAC, coronary artery calcification; DCA, deoxycholic acid